By Fineline Cube 
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP Therapeutics, a clinical-stage cell therapy company. The collaboration focuses on advancing the clinical trials of HiCM-188, a regenerative therapy for heart failure.
Global Clinical Trials
HiCM-188, developed by HELP Therapeutics, is recognized as the world’s first iPSC-derived cardiomyocyte therapy for heart failure to receive clinical trial clearance in both China and the U.S. The therapy has progressed to Phase II clinical trials in China and has initiated Phase I/II trials in the U.S., Singapore, Thailand, and other regions.-Fineline Info & Tech